Allogeneic haematopoietic stem cell transplant (HSCT) recipients are at increased risk of morbidity and mortality, often due to the development of acute or chronic graft-versus-host disease (GVHD). Low numbers or proportions of regulatory T cells (Tregs) have been reported in patients who develop GVHD. We undertook a systematic review of studies that reported the Treg composition of HSCT grafts in patients with haematological malignancies. Fourteen eligible studies were identified, eight of which stratified patients by Tregs (absolute dose or ratio to CD3+ or CD4+ cells). Meta-analyses showed that high levels of Tregs in the grafts were associated with improved overall survival [hazard ratio (HR) 0Á42, 95% confidence interval (CI) 0Á23-0Á74, P = 0Á003, 2 studies], with a significant reduction in non-relapse mortality (HR 0Á30, 95% CI 0Á14-0Á64, P = 0Á002, 2 studies) and a reduced risk of acute GVHD (relative risk (RR) 0Á59, 95% CI 0Á40-0Á89, P = 0Á01, 6 studies). The consistency of these findings strongly suggests that the Treg composition of HSCT grafts has a powerful effect on the success of allogeneic HSCT. The major challenge is to translate these findings into better selection of allografts and future donors to provide a substantial improvement in allogeneic HSCT outcomes and practice.
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Allogeneic haematopoietic stem cell transplantation (alloHSCT) offers the potential to cure many haematological disorders. However, despite continued improvements in care, it still causes severe morbidity and mortality in 15-30% of transplant recipients, depending on the patient status, disease and conditioning regimen used (Hilgendorf et al, 2012; Townsend et al, 2013) . The cause of this poor outcome may include the development of early onset (acute) or late onset (chronic) graft-versus-host disease (GVHD) (Arai et al, 2015) . GVHD is caused by allo-reactive donor T cells that are activated by host antigen presenting cells and causes a severe inflammatory disorder that affects major organs (Ferrara et al, 2009) . Regulatory T cells (Tregs) are essential for central tolerance (Morikawa & Sakaguchi, 2014) to control these immune responses and low numbers or proportions of Tregs in peripheral blood have been associated with the occurrence of acute GVHD (Rezvani et al, 2006; Fujioka et al, 2013) . The role of Treg cells on other outcomes of alloHSCT is less clear. To examine the importance of allogeneic Treg cells in alloHSCT, we have carried out a systematic review of clinical studies that reported Treg cell absolute numbers and/or as a proportion of CD3+ or CD4+ T cells within the donated graft, to determine if the concentration of Tregs within the graft influence clinical outcome following alloHSCT, and if any benefits are greater in some types of allograft settings than others. patients who had undergone an allogeneic peripheral blood, umbilical cord blood or bone marrow (BM) stem cell transplant as therapy for a haematological malignancy, and (iii) Tregs (absolute dose, ratio to other cell markers or subsets) measured in the donor graft prior to transplantation. Experimental studies of expanded or modified Tregs were excluded, as were studies that defined Tregs solely by a CD4+CD25+ phenotype without further definition of Tregs by either high levels of CD25+ or an additional cell marker.
Search strategy and study selection The titles and abstracts of all references were screened against full eligibility criteria as follows. The first 600 references were independently screened by four reviewers and discrepancies were discussed in detail to ensure consistency in interpretation of the eligibility criteria. Thereafter, two reviewers independently screened all remaining references. All of the references that met the inclusion criteria were then sent to a fifth reviewer for final eligibility assessment. The full text of papers was retrieved and screened for all those references for which a decision of eligibility could not be made from the title and abstract alone. Overlap of multiple publications was confirmed where necessary through email contact with study authors (see Acknowledgments). Studies published in Mandarin were assessed for eligibility through discussion with a Mandarin-speaking author, who then translated one eligible Chinese study (Wang et al, 2006) prior to data extraction.
Data extraction and analysis
Data were extracted onto customised data extraction forms by two reviewers independently; disagreements were resolved by consensus. Reviewers were not blinded to authorship, institutions, journals or the outcomes of trials. Recording of trial details included (i) study citation, authors and contact details; (ii) study details (objectives, design, location, setting, sample sizes, power calculations, inclusion and exclusion criteria, length of follow-up, stratification, statistical analysis methods, funding, conflicts of interest); (iii) characteristics of participants (age, gender, total number recruited, total number analysed, number of withdrawals, reasons for withdrawals, type, duration and extent of haematological malignancy); (iv) intervention (origin of donation, extent of human leucocyte antigen (HLA) matching, cell composition, timing, comparator, myeloablative/reduced intensity conditioning), T-cell depletion; (v) outcomes (overall survival, cell engraftment, disease relapse, acute GVHD, chronic GVHD and non-relapse mortality). Clarification of non-relapse mortality and survival data was sought and obtained from the authors of one study (Delia et al, 2013 ) (see Acknowledgments). Risk of individual study bias was assessed by two reviewers independently using the Research Triangle Institute (RTI) Item Bank for assessing risk of bias and confounding in observational studies (Viswanathan et al, 2013 ) adapted for the current systematic review (see Fig S1) . Overall survival was defined as the primary outcome of this review. Secondary outcomes were disease relapse, non-relapse mortality, acute GVHD, chronic GVHD and engraftment. Analysis was predominantly descriptive in nature, with conclusions drawn from tabulated results. Values reported as percentages were converted to assumed actual values based on sample sizes. Where possible, meta-analyses were performed using Review Manager (RevMan) [Computer program] (2014) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration] using random effects models; results are shown as relative risks (RR) or hazard ratios (HR) (generic inverse variance method) with 95% confidence intervals (CI). Heterogeneity was evaluated using the I 2 statistic using the thresholds defined by Higgins et al (2003) .
Results
Searches of electronic databases and reference lists identified 5586 references (see Fig 1) . From these, 48 references (17 full papers and 31 conference abstracts) were identified which described a total of 14 independent studies (987 participants) eligible for inclusion (see Table I for a summary of included study characteristics). One study (Di Ianni et al, 2011a,b; Martelli et al, 2014) administered Tregs 4 days prior to an infusion of conventional T cells (Tcons) and CD34+ cells, and compared this Treg-Tcon cohort with historical controls from previous haploidentical HSCT trials. One study cohort was derived from a randomised trial of peripheral bloodversus BM-derived HSCT (Waller et al, 2014) ; all other studies were single cohort studies. The majority of studies derived stem cells from peripheral blood; two also included recipients of BM-derived cells (Wang et al, 2006; Waller et al, 2014) , one used BM-derived cells only (Rosenzwajg et al, 2011) and one study used mixed allografts (peripheral blood and BM) (Lu et al, 2011) . No studies of Tregs measured in umbilical cord blood-derived cells were identified. Stem cell donations were obtained from sibling or related donors (7 studies), matched unrelated donors (3 studies) or a combination of both (4 studies). Tregs were defined primarily by FoxP3+ or CD25 hi markers (see Table II ) with a median absolute dose ranging from 3Á3 to 30 9 10 6 cells/kg. One study (Lu et al, 2011) (7) RIC ( dose: seven studies by absolute dose (Pabst et al, 2007; Wolf et al, 2007; Vela-Ojeda et al, 2010; Lu et al, 2011; Chaidos et al, 2012; Vendramin et al, 2014; Waller et al, 2014) and three by the ratio of Tregs to CD3+ (Rosenzwajg et al, 2011; Pastore et al, 2012; Delia et al, 2013) or CD4+ markers . The median duration of follow-up for long-term clinical outcomes ranged from 17 to 46 months.
Risk of bias and confounding
An evaluation of the risk of bias and confounding of individual studies (see Table SI ) showed that overall, study participants were selected appropriately and baseline characteristics were well documented with consistent outcome measures defined across all participants, although only one study reported details of a pre-defined protocol (Waller et al, 2014) and no study reported blinding of outcome assessors to graft composition. Attrition rates were low or accounted for by appropriate survival analysis methods in all studies.
Only eight studies reported long term outcomes. Potential confounding was identified in six studies: one study defined an arbitrary Treg stratification threshold without justification (Vela-Ojeda et al, 2010), two studies stratified patients by presence/absence of aGVHD rather than Tregs (Wang et al, 2006; Noel et al, 2008) , competing risk analysis of outcomes was not reported in six studies (Vela-Ojeda et al, 2006 , 2010 Wang et al, 2006; Noel et al, 2008; Lu et al, 2011; Rosenzwajg et al, 2011) and two studies did not perform multivariate analysis to take potential confounding factors into account (Noel et al, 2008; Vela-Ojeda et al, 2010) . Of note, the study of Treg-Tcon patients compared with historical controls (Martelli et al, 2014) only reported multivariate analysis results for disease relapse. No conflicts of interest were reported.
Overall survival
The primary outcome of this review, overall survival, was reported in seven studies (Vela-Ojeda et al, 2006 , 2010 Pabst et al, 2007; Wolf et al, 2007; Delia et al, 2013; Waller et al, 2014; Danby et al, 2016) . In four studies (Wolf et al, 2007; Vela-Ojeda et al, 2010; Delia et al, 2013; Danby et al, 2016) , which reported overall survival stratified by absolute dose or ratio of Tregs, survival rates ranged from 75% to 80% in patients who received higher dose/ratio of Tregs compared with only 33% to 49% survival in those who received a lower dose/ratio of Tregs (Fig 2A) . A significant difference in overall survival between groups stratified by Tregs was observed in three studies (Vela-Ojeda et al, 2010; Delia et al, 2013; Danby et al, 2016) whilst the fourth study (Wolf et al, 2007) found a higher dose of Tregs (above the mean value) associated with improved overall survival in patients who received myeloablative conditioning but not in those who received reduced intensity conditioning or when combined. Meta-analysis of two studies (Delia et al, 2013; Danby et al, 2016) which reported HRs with 95% CIs (high versus low Tregs) showed a significant improvement in overall survival associated with a higher ratio of Tregs to CD3+ or CD4+ cells (HR 0Á42, 95% CI 0Á23-0Á74, P = 0Á003) (Fig 3A) , whilst insufficient data were reported in two studies (notably a lack of stratified sample sizes) to allow calculation of HRs (Wolf et al, 2007; Vela-Ojeda et al, 2010) . (Delia et al, 2013; Danby et al, 2016) found the ratio of Tregs to be a significant predictor of overall survival. In the first a high Tregs/CD4+ ratio (HR 2Á22, 95% CI 1Á06-4Á54) together with younger recipient age and negative recipient cytomegalovirus serology were associated with improved overall survival, whilst in the second study (Delia et al, 2013) , a low CD3+/Tregs ratio was the only significant predictor of overall survival.
Acute GVHD
All studies reported aGVHD as an outcome. The majority of studies reported incidence of aGVHD defined as grade II-IV at either 100 or 180 days follow-up (see Table II ) which stratified patients by dose or ratio of Tregs and compared the cumulative incidence of aGVHD allowing for competing risks, seven reported a lower cumulative incidence in patients who received a higher absolute or relative dose of Tregs (Fig 2B) [the eighth study (Waller et al, 2014) did not report cumulative incidence values but found no significant difference]. In six studies that reported aGVHD rates and sample sizes in each subgroup (high or low Tregs), metaanalysis showed an average 40% reduction in aGVHD incidence associated with high Tregs (RR 0Á59, 95% CI 0Á40-0Á89, P = 0Á01), with moderate heterogeneity (I 2 = 65%)
indicative of the expected clinical heterogeneity between S. A. Fisher et al studies (Fig 3B) . In the comparison of a Treg-Tcon cohort with historical controls (Martelli et al, 2014) , the incidence of aGVHD was similar in both groups. Nine studies performed multivariate analysis of aGVHD, of which seven (Wang et al, 2006; Pabst et al, 2007; Wolf et al, 2007; Lu et al, 2011; Rosenzwajg et al, 2011; Waller et al, 2014; Danby et al, 2016) included Tregs in their statistical model [Tregs were excluded from the model in the remaining two studies (Chaidos et al, 2012; Vendramin et al, 2014) due to lack of significance from univariate analyses]. Only two studies found Tregs to be a significant predictor of aGVHD: the study by Wolf et al (2007) found Treg dose (high versus low), donor age and recipient age to be independent predictors of aGVHD, whilst Lu et al (2011) observed a significant effect of na€ ıve Tregs (CD4+CD25hiCD45RA+CD62L+) but did not report details of any other significant factors in the model.
Chronic GVHD
Chronic GVHD was reported in nine studies (Vela-Ojeda et al, 2006 , 2010 Pabst et al, 2007; Wolf et al, 2007; Delia et al, 2013; Martelli et al, 2014; Vendramin et al, 2014; Waller et al, 2014; Danby et al, 2016 ) (see Table II ) although two studies (Martelli et al, 2014; Vendramin et al, 2014) did not report results for Tregs. No study found a significant association between Tregs and development of cGVHD, either by comparing the median absolute dose in patients who developed cGVHD and those who did not (Vela-Ojeda et al, 2006 , 2010 Pabst et al, 2007) , or by comparing the cumulative incidence of cGVHD in patients stratified by median absolute dose or ratio of Tregs (Wolf et al, 2007; Delia et al, 2013; Waller et al, 2014; Danby et al, 2016) ( Fig 2C) . Only two studies (Wolf et al, 2007; Danby et al, 2016) included Tregs in multivariate analysis of cGVHD; 
Disease relapse
Seven studies reported disease relapse (Pabst et al, 2007; Wolf et al, 2007; Delia et al, 2013; Martelli et al, 2014; Vendramin et al, 2014; Waller et al, 2014; Danby et al, 2016) although one study did not report results for Tregs (Vendramin et al, 2014) . In three studies which reported relapse rates in patients stratified by Treg dose or ratio, none found any significant differences between groups (Fig 2D) alongside a fourth study which did not present relapse rates but found no significant differences between groups (Waller et al, 2014) . No significant correlation between relapse rates and Treg cell dose was found in a fifth study (Pabst et al, 2007) . However, in the comparison of Treg-Tcon with historical controls (Martelli et al, 2014) , the cumulative incidence of relapse was significantly lower in patients who received TregTcons than in historical controls (5% vs. 21%). Of four studies (Wolf et al, 2007; Delia et al, 2013; Martelli et al, 2014; Danby et al, 2016) which performed multivariate analysis, only one (Martelli et al, 2014) reported significant results for Tregs, in which Treg-Tcon adoptive immunotherapy was the only predictive factor associated with a reduced risk of disease relapse.
Non-relapse mortality
Non-relapse mortality was reported in three studies (Delia et al, 2013; Martelli et al, 2014; Danby et al, 2016) . Two studies in which patients were stratified by the median ratio of Tregs to CD4+ or CD3+ (Delia et al, 2013 ) reported a significantly lower cumulative incidence of non-relapse mortality associated with a higher ratio of Tregs relative to CD3+ or CD4+ (Fig 2E) . Results for Tregs were not reported in a third study (Martelli et al, 2014) . Metaanalysis showed that high Tregs were associated with a significant reduction in non-relapse mortality (HR 0Á30, 95% CI 0Á14-0Á64, P = 0Á002) (Fig 3C) . Three studies reported transplant-related mortality (Pabst et al, 2007; Vendramin et al, 2014; Waller et al, 2014) ; no study reported any association between transplant-related mortality and Tregs.
Engraftment
The median time to engraftment was reported in six studies . Engraftment was not defined in one study (Chaidos et al, 2012) . Median time to platelet engraftment ranged from 9 days (Vendramin et al, 2014) to 23 days (Chaidos et al, 2012) , whilst median time to neutrophil engraftment ranged from 11 days (Vendramin et al, 2014) to 21 days (Chaidos et al, 2012) . One study assessed engraftment separately in patients who received a low Treg/CD4 ratio and found a significantly higher cumulative incidence of sustained neutrophil and platelet recovery at 30 and 60 days respectively in patients who received high Tregs (97Á9%) compared with those who received low Tregs (87Á2%). In the comparison of TregTcon patients with historical controls (Martelli et al, 2014) , no differences in time to neutrophil engraftment were observed. In three studies which reported patients with graft failure, two patients had early secondary graft failure after initial neutrophil recovery , two patients failed to achieve primary sustained full engraftment (Martelli et al, 2014) and one patient experienced graft failure (Vela-Ojeda et al, 2006).
Discussion
To our knowledge this is first systematic review of the effect of the graft Tregs in the outcome of alloHSCT and provides compelling evidence for the role of graft Tregs in the outcome of alloHSCT, most crucially in relation to overall survival and specifically in relation to non-relapse mortality. Although meta-analysis was limited by the availability of full data reporting, the consistency of findings across all the identified studies strongly suggests that the Treg composition of HSCT grafts has a powerful effect on survival of alloHSCT and through a substantial reduction in non-relapse mortality including, but not necessarily limited to, a reduction in aGVHD.
In four studies which reported overall survival stratified by absolute dose or ratio of Tregs, survival rates ranged from 75% to 80% in patients who received higher dose or ratio of Tregs/CD4+ or CD3+ T cells compared with only 33-49% survival in those who received a lower dose/ratio of Tregs at between 3-5 years (Wolf et al, 2007; Vela-Ojeda et al, 2010; Delia et al, 2013; Danby et al, 2016) (Fig 2A) . Whilst a further three studies reported no association between Tregs and overall survival (Vela-Ojeda et al, 2006; Pabst et al, 2007; Waller et al, 2014) , no data were presented and this conclusion may have been drawn based on a lack of statistical power. In two studies it was also unclear how Tregs were stratified or analysed (Vela-Ojeda et al, 2006; Waller et al, 2014) .
Meta-analysis of two studies that reported sufficient data for inclusion showed a significant improvement in overall survival associated with high Tregs (HR 0Á42, 95% CI 0Á23-0Á74, P = 0Á003) (Fig 3A) . It may be argued that formal combined evidence from these two studies, representing 168 patients in total, is somewhat limited to draw robust conclusions. Nevertheless, the consistency in improved survival associated with a higher dose or ratio of Tregs to CD4+ or CD3+ T cells observed in those studies which reported data is indeed clinically significant and it is clear that the Treg component of the graft appears to be, at the very least, associated with a major effect on outcome. Individual studies lack power to determine whether the absolute graft Treg count or the Treg/CD3+ or CD4+ T cell ratio is the more reliable predictor of outcome.
The improvement in overall survival with higher absolute graft Treg count or Treg/CD3+ or CD4+ T cell ratio was also demonstrated for non-relapse mortality in two studies which reported this outcome (HR 0Á30, 95% CI 0Á14-0Á64, P = 0Á002) (Delia et al, 2013; Danby et al, 2016) . In contrast, evidence from three studies (Wolf et al, 2007; Delia et al, 2013; Danby et al, 2016) suggested no clear effect on disease relapse (Table II; Fig 2D) , although the power of this analysis is limited and differential effects of Tregs on the relapse of specific types of haematological malignancy cannot be excluded without larger studies and/or metaanalysis of individual patient data. Nevertheless, the improvement in overall survival appears to be predominantly due to a reduction in non-relapse mortality rather than disease relapse.
How might Tregs reduce non-relapse mortality? In the four studies that report on overall survival, three also reported significantly reduced aGVHD incidence in those recipients receiving higher absolute graft Treg count or Treg/ CD3+ or CD4+ T cell ratio (Wolf et al, 2007; Delia et al, 2013; Danby et al, 2016) . Meta-analysis of six studies showed a clear association between graft composition and aGVHD (RR 0Á59, 95% CI 0Á40-0Á89, P = 0Á01) (Fig 3B) . Therefore it appears that the reduction in overall survival associated with higher Tregs may be attributed at least partially to a reduction in the incidence of aGVHD. No studies showed an effect of Treg number or ratios on cGVHD, although this again must be considered with the qualification that all of the studies reporting this outcome included fewer than 100 participants and a study of this size would not be adequately powered to detect a reduction in cGVHD of up to 50% in this patient cohort.
There is however, another possible effect of Tregs in the early phases of alloHSCT, as one study showed significantly improved neutrophil and platelet engraftment in recipients of grafts with higher than median Treg/CD4 T cell ratios . This is an interesting observation as a series of animal studies have shown that some Tregs home to the BM niche, co-localise with stem cells and are associated with improved survival of stem cells within the BM niche(s) (Fujisaki et al, 2011) . Whether these putative effects of Tregs on suppression of aGVHD and improved engraftment are simply an association reflecting delayed engraftment in the presence of aGVHD or truly independent effects is not clear, as aGVHD, therapeutic immunosuppression, infection and delayed engraftment are often associated and represent a destructive pathological cycle where morbidity and mortality are multifactorial.
A further three studies examined the effects of Tregs added to allografts -either as part of a haploidentical alloHSCT using added Tregs (Martelli et al, 2014) or as part of Treg expansion protocols (Vela-Ojeda et al, 2006; Noel et al, 2008) . The study by Martelli and colleagues showed a reduction in aGVHD compared to similar historical controls that had received only haploidentical stem cell transplants without added Tregs. Studies with expanded Tregs were principally safety studies and did not have matched or comparable controls.
The clear and strong association of greater absolute number and/or Treg/total CD3+ or CD4+ Tcells with improved outcome are highly consistent with the classic observations reported by Edinger et al (2003) who used a murine model of mismatched alloHSCT in animals growing a leukaemia/ lymphoma cell line, that very high Treg/effector Tcells ratios of 1:1 allowed rapid haematological immune reconstitution without aGVHD. Our systematic review shows that the beneficial effects of Tregs may also be seen in unmanipulated grafts at a range of Treg/CD4 ratios scattered round the median of approximately 1:50. The outcome of alloHSCT has long been recognised to depend on the number of total nucleated cells and/or CD34+ stem cells (Remberger et al, 2015; Martin et al, 2016) . Other cell types in the graft have been associated with improved outcome of alloHSCT in small series or single studies. These include natural killer (NK) cells (Chaidos et al, 2012) , myeloid suppressor cells (Vendramin et al, 2014) or gamma delta T cells (Pabst et al, 2007) . Epigenetic markers possibly reflecting T cell or other immune cell numbers and/or function have been associated with reduced aGVHD [reviewed in (Paczesny et al, 2013) ]. However, none of these studies have shown effects of these cell populations on overall survival.
One potential difficulty in relating these studies is the precise measurement of Tregs in the absence of specific cell surface or intracellular markers for Tregs. Of the 14 studies measuring putative Tregs in this study, all but one (Waller et al, 2014) /kg in one study and similar ranges were seen in other studies. It seems unlikely that differences in measurement of Tregs between studies were less than the much larger difference seen between different donor grafts at any one centre. These studies, conducted at different centres, inevitably have heterogeneous indications for transplant, recipient demographics and co-morbidities, sources of allografts, conditioning and post-transplant management and immunosuppression regimen. Formal comparisons across studies were prohibited by differences in the definitions and reporting of outcomes across studies; an inherent problem in HSCT studies (Kim & Armand, 2013) . However, many studies are likely to be considerably underpowered to detect significant effects, particularly in multivariate analyses. It should also be recognised that the size of the included studies is such that there may be a risk of small study and publication bias although the current available evidence is insufficient to allow formal testing of this. Additionally, the analysis methods used in several studies are limited and do not allow for competing risks of outcomes.
To improve the resolution of studies to determine the effect of Tregs on outcomes, there is certainly a need for a collaborative effort to share individual patient data. Apart from providing adequate sample sizes for sufficient statistical power, an analysis of individual patient data combined across studies would allow comprehensive statistical modelling, incorporating disease and treatment characteristics and demographic factors to estimate the relative effects of Tregs in HSCT and evaluate the most effective predictor(s) of outcome. At the least, meta-analyses of published data would be helped by consensus on recording and reporting defined endpoints.
With the exception of Tregs associated with myeloablative, but not reduced intensity conditioning in one study (Wolf et al, 2007) , which may reflect the different power of the study in sub-groups, there is no suggestion that the benefit of high Treg/total T cells ratio is confined to particular settings of alloHSCT. While this tentative observation would require conformation by meta-analysis of individual patient data and/or larger prospective studies, it appears that a beneficial effect of Tregs is found across the spectrum of alloHSCT and is consistent with amelioration of adverse events such as aGVHD or slow engraftment that are common to all alloHSCT, albeit to a greater or lesser degree.
Current evidence on the role of Tregs in HSCT graft composition in determining the risk of aGVHD, disease relapse and survival is incomplete. As we have described, a retrospective analysis from many centres has many inherent difficulties, particularly with the likely and unquantifiable heterogeneity in the indications for transplantation, recipient demographics and co-morbidities, not to mention different sources of allografts and transplant regimens and procedures. Nevertheless, the consistency of findings from seven studies which compared the risk of aGVHD in patients with high or low absolute dose or ratio of Tregs is particularly encouraging, with all seven studies reporting a lower cumulative risk of aGVHD associated with a higher dose/ratio of Tregs. Similarly, of four studies that compared overall survival rates, all reported improved survival in patients who received a higher dose/ratio of Tregs.
Suggesting recommendations for practice based on the findings of the review would be very difficult at present. First, measurement of Treg cells at these physiological low Treg/T cell ratios is only possible by immune-phenotyping of fresh cells in research laboratories. Other epigenetic methods to quantify Treg cells have been described but present substantial technical and methodological problems. Furthermore, the data from combined retrospective studies may have hidden biases, as we have discussed.
The immediate way forward must be to confirm these retrospective studies with good multi-centre prospective studies using standardised, and ideally simplified, methods to measure Tregs. If high Treg/total T cell ratios in allografts are associated with better outcomes, then these findings could be translated into practice by one or more approaches, such as selecting donors or grafts with high Treg/total T cell ratios, conditioning donors to boost Treg/total T cell ratios, adding selected or expanded Tregs to an allograft or promoting survival and expansion of Tregs in the recipient.
Ideally, improvement of Treg/T cell ratios for HSCT allografts should use simple low cost technology that is widely applicable, not simply because of cost, but also because good randomised controlled trials with adequate power must recruit large numbers of patients. We hope the findings of this systematic review will stimulate further testing of the hypothesis that high Treg/T cell ratios in HSCT allografts are associated with better survival and as appropriate to devise widely applicable, quick and cost-effective methods to increase Treg/Tcell ratios in allografts and achieve a substantial improvement in alloHSCT outcomes.
